ArticleJournal of Cancer2011
Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies?
Article in Journal of Cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results.Cancers · 2021Review
- Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner.Clinical and experimental immunology · 2018Article
- Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer.Journal of immunology research and therapy · 2018Article
- Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial.Radiation oncology (London, England) · 2017Article
- Renal cell carcinoma: molecular characterization and evolving treatment paradigms.Current opinion in oncology · 2017Article
- Review
- Sunitinib in the treatment of metastatic renal cell carcinoma.Therapeutic advances in urology · 2016Review
- The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies.Trends in immunology · 2016Review
- The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy.Oncoimmunology · 2015Review
- Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication.Oncoimmunology · 2015Article
- Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy.World journal of urology · 2014Review
- The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities.Immunologic research · 2013Review
- Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.The Journal of biological chemistry · 2013Article
- Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves.Journal of Cancer · 2013Article
- Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer.Immunologic research · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The multikinase inhibitors Sunitinib and Sorafenib not only inhibit angiogenesis and tumor growth, but also have the potential of interacting with the function of the immune system.Presently available data seem to suggest that Sorafenib may exert immune suppressive effects, whilst the effects of Sunitinib are not so clear, being immune stimulatory in the vast majority - but not all - the studies reported.Trials of combination of these multikinase inhibitors with different types of immune manipulation - and cellular therapies in particular - should be rationally designed taking into account all these complex effects, which ultimately deserve further insights.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.